Aethlon Medical, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2014; comparative period is the fiscal year ended March 31, 2013. This is an annual report, not a standalone 2013 fourth-quarter report. Filed July 15, 2014.
Business context
Aethlon is a development-stage medical-device company. Its lead product, the Hemopurifier, is designed to remove viruses and cancer-associated exosomes from blood. The company also develops the ADAPT blood-processing platform under U.S. Department of Defense contracts and, through its 80%-owned Exosome Sciences, Inc. (ESI), pursues exosome-based diagnostics. The products were not commercially approved in the United States, and Aethlon had no product-sales revenue.
Financial performance and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue, all government contracts | $1.624 million | $1.230 million |
| Operating expenses | $4.680 million | $4.805 million |
| Operating loss | $(3.056) million | $(3.575) million |
| Net loss attributable to common stockholders | $(13.357) million | $(4.892) million |
| Basic and diluted loss per share | $(0.07) | $(0.03) |
| Cash used in operating activities | $(2.139) million | $(2.099) million |
| Cash at year-end | $1.250 million | $0.125 million |
- Revenue rose $393,765, including $1.466 million from DARPA milestones and $157,287 from a Battelle subcontract. Revenue remained dependent on government work.
- The net loss widened substantially, chiefly because of an $8.547 million noncash loss from the change in fair value of derivative liabilities. Other expenses included $1.287 million of interest and debt expense and a $583,601 litigation-settlement loss.
- At March 31, 2014, working capital was negative $14.169 million; total current liabilities were $15.649 million and total liabilities were $16.425 million. Accumulated deficit was $74.833 million. The filing reports no gross-margin figure.
- Financing activities provided $3.360 million, including $3.177 million of net common-stock proceeds and $400,000 from notes, partly offset by $217,000 of note repayments. Cash increased by $1.125 million for the year.
- The company reported that cash on hand and subsequent funds raised were insufficient for its next 12 months of funding needs. The auditor cited substantial doubt about Aethlon’s ability to continue as a going concern.
Material changes, outlook and risks
- DARPA: The original five-year fixed-price contract had potential payments of $6.794 million. DARPA exercised options for years two and three but retained options for years four and five. In February 2014, budget constraints reduced the scope and potential payments by $858,491. Management said expected cost reductions would almost entirely offset anticipated revenue reductions, subject to its assumptions.
- Clinical development: The FDA had approved an IDE for a U.S. feasibility study involving up to ten HCV-infected patients with end-stage renal disease. In May 2014, Aethlon contracted with DaVita Clinical Research for site services; projected study expenses were less than $200,000. The filing describes the study as planned and subject to site/IRB requirements and financing. Successful trials and further regulatory review would still be required for commercialization.
- ESI: ESI began operations in October 2013 and raised $1.5 million by selling minority interests, reducing Aethlon’s ownership from 100% to 80%. ESI had no revenue and reported a $404,065 operating loss for FY 2014.
- Debt restructuring and pro forma information: Certain post-year-end agreements converted or extended debt and removed anti-dilution provisions. The unaudited pro forma balance sheet shows derivative liabilities reduced from $10.679 million to zero, total liabilities from $16.425 million to $4.511 million, and total deficit from $14.730 million to $2.816 million. These are pro forma accounting effects, not cash proceeds; the transactions also involved substantial share and warrant issuance.
- Debt and dilution: The filing identifies overdue or defaulted notes and warns that additional financing is necessary. As of July 9, 2014, it disclosed $472,656 in overdue promissory notes. Common shares outstanding increased from 224.974 million at fiscal year-end to 253.396 million by July 9; options, warrants and convertible notes could cause further dilution.
- Controls and unusual items: Management concluded that disclosure controls and internal control over financial reporting were ineffective, citing insufficient segregation of duties and inadequate accounting personnel; audit adjustments and disclosure revisions resulted. The Gemini litigation was settled and dismissed, involving 7,522,854 shares placed in escrow and a $150,000 insurance payment. Management said no material unusual or infrequent fourth-quarter adjustments occurred.
- Key risks include continued losses and financing dependence, uncertain FDA approval and clinical outcomes, reliance on DARPA options and milestones, competition, manufacturing scale-up, intellectual-property challenges, product liability, and thin trading in the company’s stock.
Most important facts for investors to verify
- Current cash runway, financing completed since July 9, 2014, and the company’s ability to meet obligations as they fall due.
- Status and terms of overdue notes, restructuring agreements, and any remaining default, anti-dilution or derivative-liability exposure.
- Whether DARPA exercised years four and five options, and the revised contract scope, milestone schedule and economics.
- Whether the U.S. HCV feasibility study began, enrolled patients, and produced safety and viral-load results; distinguish reported Indian studies from FDA-reviewed U.S. evidence.
- Updated share count and fully diluted capitalization, including post-year-end conversions, warrants, options and any securities issued for debt or services.
- Progress in remediating the disclosed material weaknesses in financial reporting controls.